“Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)”, J of Skin, vol. 1, no. 3.1, p. s38, Oct. 2017, doi: 10.25251/skin.1.supp.37.